Skip to the main content.

Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Resources

Commercialization

3 min read

Case Study: Optimizing Pricing Strategies for a Medical Device Product Family

Background A leading global medical device manufacturer faced a pricing strategy challenge and partnered with Veranex (formerly Boston Healthcare...

Read More

Recent Study Co-authored by Veranex Staff Highlights Cost-effectiveness of Home Non-invasive Ventilation in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom

By developing a cost-effectiveness model and associated manuscript for home non-invasive ventilation in patients with persistent hypercapnia after an...

Read More

Veranex Supports Philips Healthcare with Writing Manuscript of Medicare Claims Study of Mobile Cardiac Monitoring

By leading the manuscript development, Veranex supported Philips Healthcare in publishing real-world evidence data supporting the use of Mobile...

Read More

Demonstrating Clinical Utility Using a Validated Methodology From the Market Research Toolkit

Veranex Director Lauren Fusfeld uses a case study to show how conjoint analysis can demonstrate to payers and health care providers the clinical...

Read More

Study by Veranex and Proteomics International Demonstrates Clinical Utility of Prognostic Test for Type 2 Diabetes Patients

By conducting a clinical utility study for Proteomics International’s PromarkerD (a blood-based test that predicts the risk of kidney disease/decline...

Read More

Published Health Economics Study Shows a High Disease Burden Associated with Stress/Mixed Urinary Incontinence to U.S. Payers

Veranex’s Commercial Strategy and Market Access team members, Manasi Datar, PhD, Li-Chen Pan, MPH, and Thomas F. Goss, PharmD, along with members...

Read More

Recent Study Co-Authored by Veranex to be Presented at ISPOR 2024

225,000 vitrectomy surgeries are performed annually in the U.S. A time-driven cost analysis conducted at a US academic hospital found the average...

Read More

Study Co-Authored by Veranex Found that Mobile Cardiac Outpatient Telemetry (MCOT) was Associated with Lower Readmissions and Healthcare Costs in Post-Stroke Monitored Patients, Compared to Implantabl

This study compares the health and economic outcomes of using mobile cardiac outpatient telemetry (MCOT) and implantable loop recorders (ILRs) for...

Read More

Study by Veranex and Thermo Fisher Highlights Payer Budget Impact of Novel Test for Kidney Transplant Rejection

By developing a U.S. payer budget impact model and associated manuscript for Thermo Fisher’s Molecular Microscope® MMDx®-Kidney (a microarray with...

Read More